Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $60.00 (from $45.00) while maintaining an Outperform rating.

The analyst commented, "BioHaven is executing on Nurtec's introduction, and despite the pandemic impact, the initial prescription figures for the first 6 weeks on market are already well ahead of our expectations. With what should be a continued successful acute indication launch, this is setting the stage for the broader and more differentiated prophylaxis indication, which is on track for a 2021 introduction. Add."

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform